← Back to Clinical Trials
Recruiting NCT06882980

NCT06882980 Comparison of Ciprofol and Propofol Under IoC1 and IoC2 Monitoring for Adenotonsillectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06882980
Status Recruiting
Phase
Sponsor Maternal and Child Health Hospital of Hubei Province
Condition Adenotonsillectomy
Study Type INTERVENTIONAL
Enrollment 236 participants
Start Date 2025-02-22
Primary Completion 2025-10-22

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 11 Years
Study Type INTERVENTIONAL
Interventions
Ciprofol groupPropofol group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 236 participants in total. It began in 2025-02-22 with a primary completion date of 2025-10-22.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to compare the Ciprofol and Propofol Under IoC1 and IoC2 Monitoring for Adenotonsillectomy Participants will be randomly allocated to two groups: Ciprofol group (Group C) and Propofol group (Group P). For those in Group C: they will be given ciprofol during anesthesia induction and maintenance .For those in Group P: they will be pgiven ciprofol during anesthesia induction and maintenanc This study evaluates ciprofol versus propofol under IoC1/IoC2 guidance in pediatric T\&A, providing evidence for ciprofol's efficacy and safety in pediatric anesthesia.

Eligibility Criteria

Inclusion Criteria: * ASA I/II, age 3-11 years, weight 13-50 kg. Endoscopic T\&A or adenoidectomy. Exclusion Criteria: * Recent upper respiratory infection. Difficult airway, organ dysfunction, developmental/psychiatric disorders. Drug allergies.

Contact & Investigator

Central Contact

Na Li, MD

✉ Email:lina@hbfy.com

📞 Telephone: Telephone:+86276349

Principal Investigator

Na Li, MD

PRINCIPAL INVESTIGATOR

Maternal and Child Health Hospital of Hubei Province

Frequently Asked Questions

Who can join the NCT06882980 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 11 Years, studying Adenotonsillectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06882980 currently recruiting?

Yes, NCT06882980 is actively recruiting participants. Contact the research team at Email:lina@hbfy.com for enrollment information.

Where is the NCT06882980 trial being conducted?

This trial is being conducted at Wuhan, China.

Who is sponsoring the NCT06882980 clinical trial?

NCT06882980 is sponsored by Maternal and Child Health Hospital of Hubei Province. The principal investigator is Na Li, MD at Maternal and Child Health Hospital of Hubei Province. The trial plans to enroll 236 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology